Dr. Dennis Wigle

Doctor Overview

Dr. Dennis Wigle is a surgeon who specializes in chest diseases, including mesothelioma and lung cancer. He also conducts research in immunotherapy and genetics. He sees patients at the Mayo Clinic Cancer Center in Rochester, Minnesota.

Dr. Wigle first earned his master’s and doctorate degrees in Cell Biology from Queen’s University in Kingston, Canada. He then earned his medical degree from the University of Toronto. He has treated patients for more than 20 years and has contributed to more than 200 scholarly papers. He served on the board of the Mesothelioma Applied Research Foundation from 2016 through 2018.

Dr. Wigle is currently the lead investigator on several clinical trials. One study will examine surgery for mesothelioma after radiation therapy. Another study will investigate the use of chemotherapy after surgery and radiation for mesothelioma. The research teams hope to complete the trials in December 2024.

Doctor Fast Facts

Main Specialty: Thoracic Surgery

Other Interests & Specialties: Esophageal cancer, lung cancer, mesothelioma, thoracic oncology and thymic tumor.

Certifications, Awards & Accolades: American College of Surgeons Fellowship, CHEST Foundation/LUNGevity Foundation Clinical Research Award in Lung Cancer, NIH K12 Career Development Award, Surgery Subspecialty Teaching Award, Mayo Clinic Early Career Development Award for Clinician Scientists

Education & Experience:

• MSc and PhD degrees in Cell Biology from Queen’s University in Kingston, Canada
• Medical Degree from University of Toronto
• Postdoctoral Research Fellowship in Molecular and Medical Genetics with the Samuel Lunenfeld Research Institute, Mount Sinai Hospital

Publications

Lobar or sublobar resection for peripheral stage ia non-small-cell lung cancer. N Engl J Med. 2023 Feb 9;388(6):489–98.

Perioperative mortality and morbidity after sublobar versus lobar resection for early-stage non-small-cell lung cancer: post-hoc analysis of an international, randomised, phase 3 trial (CALGB/Alliance 140503). Lancet Respir Med. 2018 Dec;6(12):915–24.

MicroRNA and mRNA features of malignant pleural mesothelioma and benign asbestos-related pleural effusion. Biomed Res Int. 2015;2015:635748.

Surgical management of lung cancer. Semin Respir Crit Care Med. 2011 Feb;32(1):69–77.